Vitiligo Medication

Updated: Jul 20, 2022
  • Author: Shekhar Neema, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print

Medication Summary

The topical Janus kinase (JAK) inhibitor, ruxolitinib, is the first drug approved for vitiligo repigmentation. Other drugs (eg, topical corticosteroids, topical calcineurin inhibitors, psoralens, immunomodulators, and vitamin D analogs) have been used for treating vitiligo. 


Dermatologics, JAK Inhibitors

Class Summary

Mechanism of action may involve disruption of interferon-gamma signaling and Janus kinase pathways involved in vitiligo.

Ruxolitinib topical (Opzelura)

Indicated for topical treatment of nonsegmental vitiligo in adults and adolescents aged 12 years and older.